Triple Negative Breast Cancer — CAR T Cell and Targeted Therapy

Triple negative breast cancer, CAR T cell therapy, and targeted cancer treatments explained through new breakthrough research. Unique Houston Methodist Research Institute study reveals how engineered immune cells plus targeted therapies may prevent early spread and recurrence. Learn how emerging immunotherapy for breast cancer could change outcomes for early stage triple negative breast cancer patients and survivors. What You'll Learn: Why triple negative breast cancer (TNBC) is more aggressive and accounts for about 1 in 6 breast-cancer diagnoses worldwide. How the lack of hormone and HER2 receptors in TNBC limits standard treatment options and drives high recurrence within 3 years. What CAR T cell therapy is, how it works, and why six products are FDA-approved for blood cancers but none yet for solid tumors like breast cancer. How pairing targeted cancer treatments with CAR T cell therapy may help control early spread and recurrence in triple negative breast cancer. What the new Cancer Letters study from Houston Methodist Research Institute found about engineered immune cells in early stage breast cancer. The potential impact of this new cancer treatment breakthrough on cancer recurrence prevention and long-term outcomes for TNBC patients. Key safety, feasibility, and research questions that must be answered before CAR T-based immunotherapy for breast cancer reaches the clinic. How current findings may shape future clinical trials and what patients and clinicians should watch for in breast cancer research. About the Guest: About the Guest: Gabriel Duda, Ph.D., is the scientific director of transplant oncology and therapeutics at Houston Methodist Research Institute. His work focuses on cutting-edge cellular therapies and targeted approaches to prevent cancer spread and recurrence. As lead author of the recent Cancer Letters study on CAR T cells and triple negative breast cancer, he brings first-hand insight into where breast cancer research and immunotherapy are headed next.